Overproduction of cortisol hormone leads to Cushing’s syndrome. Also, exposure to glucocorticoids is expected to be one of the prime causes of the disease. Glucocorticoids are usually prescribed for diseases such as asthma, rheumatoid arthritis (RA), and lupus. Pituitary tumor, adrenal tumors, and ectopic adrenocorticotropic hormone (ACTH)-producing tumors result in increased cortisol level, eventually becoming a cause for Cushing’s syndrome. According to the American Association of Neurological Surgeons (AANS) 2019 factsheet, Cushing’s syndrome is more common in females than males and majorly affects adults aged 20–50 years.
Some common symptoms of the disease include a fatty lump between shoulders; weight gain; wide purple stretch marks mainly on abdomen, breasts, hips, and under the arms; thin arms and legs; weak muscles; easy bruising; and increased fat around the base of neck. The disease can be diagnosed through late-night salivary cortisol test, 24-hour urinary free-cortisol test, dexamethasone–CRH test, and low-dose dexamethasone suppression test (LDDST).
According to the research, many drugs being developed for Cushing’s syndrome are administered intravenously. It has been found that intravenous route of administration surpasses gastrointestinal tract, and there is rapid onset of drug effect.
There are several companies that are involved in developing therapeutics for Cushing’s syndrome have shown positive results of clinical trials. For instance, in March 2019, Strongbridge Biopharma plc announced positive results of extended evaluation phase of the pivotal Phase III Sonics study of Recorlev, a cortisol synthesis inhibitor. According to the results of the study, Recorlev demonstrated long-term efficacy to reduce mean urinary free cortisol (mUFC), as well as cardiovascular risk markers such as weight and low-density lipoprotein (LDL)-cholesterol.
Companies are actively involved in advancing their pipeline candidates for the treatment of this rare disease. For instance, Strongbridge Biopharma plc is planning to submit a new drug application (NDA) to the USFDA for Recorlev, which is indicated for the treatment of Cushing’s syndrome. Similarly, in January 2019, Corcept Therapeutics Incorporated was issued a new patent by the United States Patent and Trademark Office (USPTO), covering the use of Korlym in combination with CYP3A inhibitors for the treatment of patients with Cushing’s syndrome.
The global Rett Syndrome Therapeutics Market research report, published by Value Market Research, is designed to offer various market framework such as market size, portion, trends, growth path, value and factors that impact the current market dynamics over the forecast period 2020-2027.
Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the rett syndrome therapeutics market include AMO Pharma Ltd, Amorsa Therapeutics Inc, Anavex Life Sciences Corp, Apteeus, ArmaGen Inc, AveXis Inc, BioElectron Technology Corp, Biohaven Pharmaceutical Holding Company Ltd, Eloxx Pharmaceuticals Ltd, GW Pharmaceuticals Plc.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Rett Syndrome Therapeutics Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/rett-syndrome-therapeutics-market/download-sampleMarket DynamicsThe Rett syndrome therapeutics market is expected to gain traction during the forecast period.
An increase in global healthcare expenditure and increased spending related to public healthcare programs will contribute to market growth.
On the other hand, certain factors restraining the Rett syndrome therapeutics market including high treatment cost, high expenditure related to R, unavailability of approved drugs, no definite cure, and imposition of regulatory laws.The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis.
